Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA grants breakthrough therapy designation to Takeda narcolepsy drug candidate

The drug would be a novel treatment for narcolepsy type 1, if approved.

By Brian Buntz | July 28, 2021

TakedaTakeda (NYSE:TAK) has won breakthrough therapy designation from FDA for TAK-994, an experimental oral orexin agonist. Now in a Phase 2 trial, TAK-994 is formulated to selectively target orexin 2 receptors. Orexin is a neuropeptide that supports normal wakefulness. Orexin deficiency is associated with narcolepsy.

Takeda is testing the potential of TAK-994 to treat excessive daytime sleepiness in people with narcolepsy type 1 (NT1), which involves a disturbance of sleep-wake cycles and the presence of cataplexy. Cataplex itself involves a sudden muscle weakness occurring when a person is awake.

Currently, the majority of therapies for NT1 are repurposed, including a range of stimulants and antidepressants. In addition, FDA has indicated sodium oxybate (Xyrem) for cataplexy in narcolepsy and excessive daytime sleepiness, which is effective but has a risk of respiratory depression and has significant potential for abuse.

Following the announcement, Takeda shares ticked up 2.39%, or $0.40, to $17.17, in mid-afternoon trading.


Filed Under: clinical trials, Drug Discovery, Neurological Disease

 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50